We haven't covered Aimmune Therapeutics, Inc. (AIMT) as much as we should, barring an article comparing Aimmune and its distant competitor DBV Technologies (DBVT), where we said that AIMT is probably the better investment. Late last year, after DBVT withdrew its US marketing application for its Viaskin product targeting peanut allergy, AIMT spiked overnight, especially after filing its own NDA/BLA for AR101 in peanut allergy. However, problems at the FDA having to do with politics delayed the approval and took the stock down and kept it subdued. Lately, though, we are